Cadonilimab plus chemo for PD-L1 negative lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that does not have the PD-L1 protein. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-squamous non-small cell lung cancer (stage IIIB, IIIC, or IV) that has not spread to the brain or other organs in a problematic way.
- Your cancer does not have the PD-L1 protein (PD-L1 negative).
- You have not received prior treatment for advanced cancer, except for chemo or radiation given before surgery or after, if that was more than 6 months ago.
- You do not have certain genetic changes (EGFR, ALK, or ROS1 mutations) in your cancer.
- You are generally active (ECOG score 0 or 1) and your organs work well enough.
- You have at least one tumor that can be measured on scans and are willing to provide a tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.